Alankit joins forces with Digital Swiss Gold to enable buying of Swiss gold

Alankit joins forces with Digital Swiss Gold to enable buying of Swiss gold

Alankit Imaginations has entered into a partnership with Digital Swiss Gold (DSG), a digital platform that enables investors to purchase and hold physical gold digitally in Switzerland and also sell and send gold through a mobile app. The partnership will tap into the more than 25 million customer base of Alankit Imaginations’ parent company Alankit, […]

Hearing aid company Sonova to acquire Sennheiser consumer unit for €200m

Hearing aid company Sonova to acquire Sennheiser consumer unit for €200m

Sonova, a Swiss hearing care solutions provider, has agreed to acquire the consumer electronics division of German audio company Sennheiser electronic for €200m. The Sennheiser consumer division focuses on selling headphones and hearables for private customers. It is said to be an excellent fit with the Swiss firm’s strategy to steer innovation in hearing experience […]

Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition

Roivant Sciences enters into $7.3bn merger with Montes Archimedes Acquisition

Roivant Sciences has agreed to merge with Montes Archimedes Acquisition (MAAC), a Nasdaq-listed special purpose acquisition company, in a deal that values the Swiss biopharma company at $7.3 billion. Montes Archimedes Acquisition is sponsored by health care investment firm Patient Square Capital. The deal is expected to enable Roivant Sciences to get a listing on […]

Chubb Hartford merger : Swiss insurer offers to acquire The Hartford for $23.2bn

Chubb Hartford merger : Swiss insurer offers to acquire The Hartford for $23.2bn

Chubb Hartford merger : Swiss property and casualty insurance company Chubb has offered to acquire The Hartford Financial Services Group for $65 per share or $23.24 billion in a cash-cum-stock deal. The Hartford Financial Services Group is a US-based property and casualty insurance company. According to Chubb, the merger of the companies will be strategically […]

VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome

VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome

VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS clinical trial. This trial will evaluate the efficacy and safety of apraglutide, a synthetic glucagon-like peptide-2 (GLP-2) analog, in treating patients with Short Bowel Syndrome (SBS) with intestinal failure (SBS-IF). The STARS trial marks the largest phase […]

Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn

Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn

German pharma company Boehringer Ingelheim has signed a deal worth €1.18 billion to acquire NBE-Therapeutics, a clinical-stage Switzerland-based biotech company, focused on developing antibody-drug conjugates (ADCs) and advancing targeted cancer therapies. Through the acquisition, Boehringer Ingelheim will gain access to the Swiss firm’s iADC platform, which is capable of creating immune stimulatory ADCs with an […]

NEC to acquire Swiss fintech company Avaloq for $2.2bn

NEC to acquire Swiss fintech company Avaloq for $2.2bn

NEC acquisition of Avaloq : NEC Corporation, a Japanese IT and electronics company, has agreed to acquire Avaloq Group, a Swiss financial software company, for CHF 2.05 billion ($2.27 billion). Avaloq is a provider of digital banking solutions, core banking software, and wealth management technology. The Swiss fintech company is claimed to have more than […]

Novartis reports positive results for Aimovig in phase 2 episodic migraine trial

Novartis reports positive results for Aimovig in phase 2 episodic migraine trial

Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients with episodic migraine (EM). The results of the mid-stage trial – NCT01952574 are being presented by the Swiss drugmaker at the 18th Migraine Trust Virtual Symposium. The five-year, open-label treatment […]